The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies

Conference Reports for NATAP

AASLD
The Liver Meeting
Boston MA
November 2016


The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies

	Reported by Jules Levin AASLD 2016 Nov 11-15 Boston, MA